Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Nov 20, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	391	234	106	395	405	752
Market Cap Growth	29.30%	120.08%	-73.16%	-2.30%	-46.16%	16.23%
Enterprise Value	460	301	121	363	241	640
Last Close Price	1.79	1.24	0.58	2.26	2.80	6.32
PS Ratio	2.15	1.20	0.36	1.87	1.37	2.24
PB Ratio	-5.51	-7.64	20.30	5.34	1.63	1.90
P/TBV Ratio	-	-	-	-	8.36	15.50
EV/Sales Ratio	2.71	1.55	0.41	1.71	0.82	1.91
EV/EBITDA Ratio	104.25	-	39.44	-	-	-
Debt / Equity Ratio	-2.05	-3.41	30.07	2.56	0.51	0.27
Debt / EBITDA Ratio	10.97	-	18.82	-	-	-
Asset Turnover	0.77	0.65	0.66	0.36	0.42	0.38
Inventory Turnover	1.38	2.13	0.77	1.67	0.72	0.91
Quick Ratio	1.01	0.82	1.01	0.79	1.59	0.90
Current Ratio	1.52	1.18	1.43	1.04	1.98	1.49
Return on Equity (ROE)	-	-	-237.83%	-175.37%	-119.82%	-54.27%
Return on Assets (ROA)	-9.37%	-9.30%	-4.89%	-24.27%	-15.41%	-19.74%
Return on Capital (ROIC)	-32.60%	-23.56%	-10.17%	-44.71%	-24.88%	-30.24%
Earnings Yield	-11.78%	-22.23%	-88.77%	-71.32%	-95.09%	-37.20%
FCF Yield	-9.87%	-10.01%	-69.03%	-63.99%	-27.35%	-35.13%
Buyback Yield / Dilution	-9.55%	-2.56%	-10.14%	-19.85%	-16.95%	-104.00%
Total Shareholder Return	-9.55%	-2.56%	-10.14%	-19.85%	-16.95%	-104.00%

Source: S&P Capital IQ. Standard template. Financial Sources.